Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners

BACKGROUND: Levodopa‐carbidopa intestinal gel (LCIG, designated in the United States as carbidopa‐levodopa enteral suspension, CLES) was approved in the United States in 2015 for the treatment of refractory motor fluctuations in individuals with Parkinson disease (PD). Many neurologists in the Unite...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mov Disord Clin Pract
Glavni autori: Burack, Michelle, Aldred, Jason, Zadikoff, Cindy, Vanagunas, Arvydas, Klos, Kevin, Bilir, Bahri, Fernandez, Hubert H., Standaert, David G.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Reviews
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6174493/
https://ncbi.nlm.nih.gov/pubmed/30363427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mdc3.12630
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items